Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 3, 2008 - Issue 9
Submit an article Journal homepage
184
Views
2
CrossRef citations to date
0
Altmetric
Reviews

Development and prospects for bispecific antibody-based therapeutics in cancer and other applications

Lawrence G Lum Professor of Medicine and Professor of Immunology and Microbiology, Scientific Director of BMT and Immunotherapy Program, Wayne State University, Member Barbara Ann Karmanos Cancer Institute, Hudson-Webber Cancer Research Center, 4100 John R., 7th Floor, Rm 740.1, Detroit, Michigan, MI 48201, USA +1 313 576 8326; +1 313 576 8939; [email protected]
, MD DSc &
Zaid Al-Kadhimi Professor of Medicine and Professor of Immunology and Microbiology, Scientific Director of BMT and Immunotherapy Program, Wayne State University, Member Barbara Ann Karmanos Cancer Institute, Hudson-Webber Cancer Research Center, 4100 John R., 7th Floor, Rm 740.1, Detroit, Michigan, MI 48201, USA +1 313 576 8326; +1 313 576 8939; [email protected]
Pages 1081-1097 | Published online: 21 Aug 2008

Bibliography

  • Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-21
  • Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-80
  • Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5
  • Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions [review]. Curr Opin Oncol 1997;9:139-45
  • Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4
  • Liu Z, Savoldo B, Huls H, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res 2002;159:123-33
  • Raso V, Griffin T. Hybrid antibody with dual specificity for the delivery of ricin to immunoglobin bearing target cells. Cancer Res 1981;41:2073-8
  • Titus JA, Perez P, Kaubisch A, et al. Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol 1987;139:3153-8
  • Perez P, Titus JA, Lotze MT, et al. Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. J Immunol 1986;137:2069-72
  • Segal DM, Garrido MA, Perez P, et al. Targeted cytotoxic cells as a novel form of cancer immunotherapy. Mol Immunol 1988;25:1099-103
  • Perez P, Hoffman RW, Shaw S. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985;316:354-6
  • Renner C, Held G, Ohnesorge S, et al. Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Cancer Immunol Immunother 1997;44:70-6
  • Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J Histochem Cytochem 2001;49:911-7
  • Zeidler R, Mysliwietz J, Csanady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-6
  • Kiewe P, Hasmuller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006;12:3085-91
  • Cao Y, Lam L. Bispecific antibody conjugates in therapeutics. Adv Drug Deliv Rev 2003;55:171-97
  • Teillaud JL. Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges. Expert Opin Biol Ther 2005;5(Suppl 1):S15-27
  • Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999;48:346-52
  • Rivoltini L, Barracchini KC, Viggiano V, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995;55:3149-57
  • Cohen SB, Katsikis PD, Feldmann M, Londei M. IL-10 enhances expression of the IL-2 receptor alpha chain on T cells. Immunology 1994;83:329-32
  • Concha A, Cabrera T, Ruiz-Cabello F, Garrido F. Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer Suppl 1991;6:146-54
  • Blades RA, Keating PJ, McWilliam LJ, et al. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995;46:681-6
  • Browning M, Petronzelli F, Bicknell D, et al. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 1996;47:364-71
  • Redondo M, Concha A, Oldiviela R, et al. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res 1991;51:4948-54
  • Torres MJ, Ruiz-Cabello F, Skoudy A, et al. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tissue Antigens 1996;47:372-81
  • Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94
  • Smyth MJ, Strobl SL, Young HA, et al. Regulation of lymphokine-activated killer activity and pore- forming protein gene expression in human peripheral blood CD8+T lymphocytes. Inhibition by transforming growth factor-β. J Immunol 1991;146:3289-97
  • Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317-22
  • Tartour E, Blay JY, Dorval T, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol 1996;14:1697-703
  • Zeidler R, Reisbach G, Wollenberg B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163:1246-52
  • Klein SC, Boer LH, de Weger RA, et al. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 × CD19. Scand J Immunol 1997;46:452-8
  • Nam JS, Terabe M, Kang MJ, et al. Transforming growth factor {beta} subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008;68:3915-23
  • Mullbacher A, Lobigs M, Tha Hla R, et al. Antigen-dependent release of IFN-gamma by cytotoxic T cells up-regulates Fas on target cells and facilitates exocytosis-independent specific target cells lysis. J Immunol 2002;169:145-50
  • Zeytun A, Hassuneh M, Nagarkatti M, Nagarkatti PS. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood 1997;90:1952-9
  • Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by Caspase inhibition. J Immunol 1999;162:3273-9
  • Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997;158:4521-4
  • O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82
  • Karas M, Zaks TZ, Yakar S, et al. TCR stimulation protects CD8+T cells from CD95 mediated apoptosis. Human Immunol 2001;62:32-8
  • Grabert RC, Smith J, Tiggs J, et al. Anti-CD3 activated T cells armed with OKT3 × herceptin bispecific antibody, survive and divide, and secrete cytokines and chemokines after multiple cycles of killing directed at Her2/neu+Tumor Targets [abstract]. Am Assoc Cancer Res 2003;44:656a
  • Grabert RC, Cousens LP, Smith JA, et al. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res 2006;12:569-76
  • de Gast GC, van Houten AA, Haagen IA, et al. Clinical experience with CD3 × CD19 bispecific antibodies in patients with B cell malignancies. J Hematother 1995;4:433-7
  • Molema G, Cohen Tervaert JW, Kroesen BJ, et al. CD3 directed bispecific antibodies induce increased lymphocyte- endothelial cell interactions in vitro. Br J Cancer 2000;82:472-9
  • Kosterink JG, de Jonge MW, Smit EF, et al. Pharmacokinetics and scintigraphy of indium-111-DTPA-MOC-31 in small-cell lung carcinoma. J Nucl Med 1995;36:2356-62
  • Kroesen BJ, Nieken J, Sleijfer DT, et al. Approaches to lung cancer treatment using the CD3 × EGP-2-directed bispecific monoclonal antibody BIS-1. Cancer Immunol Immunother 1997;45:203-6
  • Weiner LM, Clark JI, Davey M, et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 1995;55:4586-93
  • Borghaei H, Alpaugh RK, Bernardo P, et al. Induction of adaptive Anti-HER2/neu immune responses in a phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. J Immunother 2007;30:455-67
  • Hartmann F, Renner C, Jung W, et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 2001;7:1873-81
  • Valone FH, Kaufman PA, Guyre PM, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 1995;13:2281-92
  • McCall AM, Adams GP, Amoroso AR, et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol 1999;36:433-45
  • Schwaab T, Lewis LD, Cole BF, et al. Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI × anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu. J Immunother 2001;24:79-87
  • James ND, Atherton PJ, Jones J, et al. A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+advanced prostate cancer. Br J Cancer 2001;85:152-6
  • Posey JA, Raspet R, Verma U, et al. A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. J Immunother 1999;22:371-9
  • Fury MG, Lipton A, Smith KM, et al. A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother 2008;57:155-63
  • Borchmann P, Schnell R, Fuss I, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 2002;100:3101-7
  • Nitta T, Sato K, Yagita H, et al. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990;335:368-71
  • Lamers CHJ, van de Griend RJ, Braakman E, et al. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int J Cancer 1992;51:973-9
  • Lamers CH, Bolhuis RL, Warnaar SO, et al. Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody. Int J Cancer 1997;73:211-9
  • Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995;87:1463-9
  • Morecki S, Lindhofer H, Yacovlev E, et al. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood 2006;107:1564-9
  • Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001;98:2526-34
  • Sebastian M, Passlick B, Friccius-Quecke H, et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study. Cancer Immunol Immunother 2007;56:1637-44
  • Burges A, Wimberger P, Kumper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13:3899-905
  • Riechelmann H, Wiesneth M, Schauwecker P, et al. Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother 2007;56:1397-406
  • Sen M, Wankowski DM, Garlie NK, et al. Use of anti-CD3 × anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu Tumors. J HematotherStem Cell Res 2001;10:247-60
  • Lum HE, Miller M, Davol PA, et al. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas. Anticancer Res 2005;25:43-52
  • Lum LG, Davol P, Grabert R, et al. Targeting pancreatic cancer with armed activated T cells directed at Her2/neu receptors [abstract]. Exp Hematol 2002;30:56
  • Davol PA, Smith JA, Kouttab N, et al. Anti-CD3 × Anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing SCID-Beige mice. Clin Prostate Cancer 2004;3:112-21
  • Lum LG, Rathore R, Dizon D, et al. Induction of immune responses and improved survival after infusions of T cells armed with anti-CD3 × anti-Her2/neu bispecific antibody in stage IV breast cancer patients (phase I). Blood 2007;110:807a
  • Davol PA, Gall JM, Young WB, et al. Clinical and immune responses in breast and hormone refractory prostate cancer patients treated with T cells armed with anti-CD3 × anti-HER2/neu bispecific antibody in a Phase I clinical trial [abstract]. Exp Hematol 2005;33:53(Suppl 1)
  • Guo Y-J, Che X-Y, Shen F, et al. Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med 1997;3:451-5
  • Alvarez-Vallina L, Hawkins RE. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 1996;26:2304-9
  • Renner C, Jung W, Sahin U, et al. The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur J Immunol 1995;25:2027-33
  • Mazzoni A, Mezzanzanica D, Jung G, et al. CD3-CD28 costimulation as a means of avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Cancer Res 1996;56:5443-9
  • Demanet C, Brissinck J, De Jong J, Thielemans K. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood 1996;87:4390-8
  • Renner C, Jung W, Sahin U, et al. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994;264:833-5
  • Bohlen H, Hopff T, Manzke O, et al. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 1993;82:1803-12
  • Hombach A, Tillmann T, Jensen M, et al. Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity. Clin Exp Immunol 1997;108:352-7
  • Jung G, Brandl M, Eisner W, et al. Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ T-cell activation and therapeutic efficacy. Int J Cancer 2001;91:225-30
  • Fitzer-Attas CJ, Eshhar Z. Tyrosine kinase chimeras for antigen-selective T-body therapy. Adv Drug Deliv Rev 1998;31:171-82
  • Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90:720-4
  • Hwu P, Shafer GE, Treisman JS, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993;178:361-6
  • Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995;55:3369-73
  • Fitzer-Attas CJ, Eshhar Z. Tyrosine kinase chimeras for antigen-selective T-body therapy. Adv Drug Delivery Rev 1998;31:171-82
  • Altenschmidt U, Moritz D, Groner B. Specific cytotoxic T lymphocytes in gene therapy. J Mol Med 1997;75:259-66
  • Kershaw MH, Westwood JA, Parker LL, et al. A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12:6106-15
  • Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994;91:4318-22
  • Plavec I, Agarwal M, Ho KE, et al. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy. Gene Ther 1997;4:128-39
  • Quinn ER, Lum LG, Trevor KT. T cell activation modulates retrovirus-mediated gene expression. Hum Gene Ther 1998;9:1457-67
  • Somasundaram C, Sundarapandiyan K, Keler T, et al. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells. Hum Antibodies 1999;9:47-54
  • Schoonjans R, Willems A, Schoonooghe S, et al. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol 2000;165:7050-7
  • Wang XB, Zhao BF, Zhao Q, et al. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently. J Biochem 2004;135:555-65
  • Song LP, Cheng JL, Wang XB, et al. A new model of trispecific antibody resulting the cytotoxicity directed against tumor cells. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2003;35:503-10
  • Wong WM, Vakis SA, Ayre KR, et al. Rheumatoid arthritis T cells produce Th1 cytokines in response to stimulation with a novel trispecific antibody directed against CD2, CD3, and CD28. Scand J Rheumatol 2000;29:282-7
  • Brischwein K, Schlereth B, Guller B, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006;43:1129-43
  • Molhoj M, Crommer S, Brischwein K, et al. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis. Mol Immunol 2007;44:1935-43
  • Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005;115:98-104
  • Lum LG, Rathore R, Dizon D, et al. Induction of immune responses and improved survival after infusions of T cells armed with Anti-CD3 × Anti-Her2/Neu bispecific antibody in stage IV breast cancer patients (phase I). Blood 2007;110:2724a
  • Ren-Heidenreich L, Davol PA, Kouttab NM, et al. Redirected T-cell cytotoxicity to EpCAM over-expressing adenocarcinomas by a novel recombinant antibody,E3Bi, in vitro and in an animal model. Cancer 2004;100:1095-103
  • McCall AM, Shahied L, Amoroso AR, et al. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 2001;166:6112-7
  • Haagen IA, de Lau WB, Bast BJ, et al. Unprimed CD4+and CD8+T cells can be rapidly activated by a CD3 × CD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunol Immunother 1994;39:391-6
  • Renner C, Held G, Ohnesorge S, et al. Role of naive and memory T cells in tumor cell lysis mediated by bi- specific antibodies. Immunobiology 1997;197:122-32
  • Goldenberg DM, Chatal JF, Barbet J, et al. Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther 2007;2:19-31
  • Sharkey RM, Karacay H, McBride WJ, et al. Bispecific antibody pretargeting of radionuclides for immuno single-photon emission computed tomography and immuno positron emission tomography molecular imaging: an update. Clin Cancer Res 2007;13:s5577-85
  • McBride WJ, Zanzonico P, Sharkey RM, et al. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med 2006;47:1678-88
  • Moosmayer D, Berndorff D, Chang CH, et al. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors. Clin Cancer Res 2006;12:5587-95
  • Venisnik KM, Olafsen T, Loening AM, et al. Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors. Protein Eng Des Sel 2006;19:453-60
  • Khaw BA, Tekabe Y, Johnson LL. Imaging experimental atherosclerotic lesions in ApoE knockout mice: enhanced targeting with Z2D3-anti-DTPA bispecific antibody and 99mTc-labeled negatively charged polymers. J Nucl Med 2006;47:868-76
  • Munitz A, Bachelet I, Levi-Schaffer F. Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. J Allergy Clin Immunol 2006;118:1082-9
  • Lum LG, Fok H, Sievers R, et al. Targeting of Lin-Sca+hematopoietic stem cells with bispecific antibodies to injured myocardium. Blood Cells Mol Dis 2004;32:82-7
  • Lee RJ, Fang Q, Davol PA, et al. Antibody targeting of stem cells to infarcted myocardium. Stem Cells 2007;25:712-7
  • Zhao TC, Tseng A, Yano N, et al. Targeting human CD34+hematopoietic stem cells with anti-CD45 × anti-myosin light chain bispecific antibody preserves cardiac function in myocardial infarction. J Appl Physiol 2008;104:1793-800
  • Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1. N Engl J Med 2008;358:2698-703
  • Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005;5:397-405
  • Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003;170:4905-13
  • van der Most RG, Currie A, Robinson BW, Lake RA. Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 2006;66:601-4
  • Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57
  • Fowler DH, Odom J, Steinberg SM, et al. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006;12:1150-60
  • Davico BL, De Monte LB, Spagnoli GC, et al. Bispecific monoclonal antibody anti-CD3 × anti-tenascin: an immunotherapeutic agent for human glioma. Int J Cancer 1995;61:509-15
  • Nitta T, Sato K, Okumura K, Ishii S. Induction of cytotoxicity in human T cells coated with anti- glioma × anti-CD3 bispecific antibody against human glioma cells. J Neurosurg 1990;72:476-81
  • Kaneko T, Fusauchi Y, Kakui Y, et al. A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells. Blood 1993;81:1333-41
  • Katayose Y, Kudo T, Suzuki M, et al. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth. Cancer Res 1996;56:4205-12
  • Bolhuis RLH, Lamers CHJ, Goey SH, et al. Adoptive immunotherapy of ovarian carcinoma with BS-MAb-targeted lymphocytes: a multicenter study. Int J Cancer 1992;78-81
  • Zhu Z, Ghose T, Lee SH, et al. Tumor localization and therapeutic potential of an antitumor-anti-CD3-heteroconjugate antibody in human renal cell carcinoma xenograft models. Cancer Lett 1994;86:127-34
  • Luiten RM, Coney LR, Fleuren GJ, et al. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br J Cancer 1996;74:735-44
  • Jost CR, Titus JA, Kurucz I, Segal DM. A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL. Mol Immunol 1996;33:211-9
  • Kroesen BJ, ter Haar A, Willemse P, et al. Local antitumor treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother 1993;37:401-7
  • Bohlen H, Manzke O, Patel B, et al. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 1993;43:4310-4
  • Anderson PM, Crist W, Hasz D, et al. G19.4(αCD3) × B43(αCD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen- positive cytotoxic T cells. Blood 1992;80:2826-34
  • Bejeck BE, Wang D, Berven E, et al. Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen. Cancer Res 1995;55:2346-51
  • de Gast GC, Haagen I-A, van Houten AA, et al. CD8 T cell activation after intravenous administration of CD3 × CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 1995;40:390-6
  • Chapoval AI, Nelson H, Thibault C. Anti-CD3 × anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes. J Immunol 1995;155:1296-303
  • Kuwahara M, Kuroki M, Arakawa F, et al. A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes. Anticancer Res 1997;16:2661-8
  • Brossart P, Stuhler G, Flad T, et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998;58:732-6
  • Renner C, Bauer S, Sahin U, et al. Cure of disseminated xenografted human Hodgkin's tumors by bispecifc monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model. Blood 1996;87:2930-7
  • Pohl C, Denfeld R, Renner C, et al. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma. Int J Cancer 1993;54:820-27
  • Katzenwadel A, Schleer H, Gierschner D, et al. Construction and in vivo evaluation of an anti-PSA × anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anticancer Res 2000;20:1551-5
  • Hombach A, Tillmann T, Jensen M, et al. Specific activation of resting T cells against CA19-9+tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody. J Immunother 1997;20:325-33
  • Kostelny SA, Link BK, Tso JY, et al. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer 2001;93:556-65
  • Negri DR, Tosi E, Valota O, et al. In vitro and in vivo stability and anti-tumour efficacy of an anti- EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer 1995;72:928-33
  • Reusch U, Sundaram M, Davol PA, et al. Anti-CD3 × anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 2006;12:183-90
  • Brischwein K, Schlereth B, Guller B, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006;43:1129-43
  • Compte M, Blanco B, Serrano F, et al. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA × anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007;14:380-8
  • Wang D, Wu GJ, Wang H, et al. Comparison of biologic activity of two anti-PSA/anti-CD3 bispecific single-chain antibodies. Zhonghua Nan Ke Xue 2007;13:8-12
  • Tita-Nwa F, Moldenhauer G, Herbst M, et al. Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells. Cancer Immunol Immunother 2007;56:1911-20
  • Amann M, Brischwein K, Lutterbuese P, et al. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res 2008;68:143-51
  • Herrmann T, Grosse-Hovest L, Otz T, et al. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 2008;68:1221-7
  • Larbouret C, Robert B, Linard C, et al. Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice. Int J Radiat Oncol Biol Phys 2007;69:1231-7
  • Hammond SA, Lutterbuese R, Roff S, et al. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res 2007;67:3927-35
  • Ruf P, Gires O, Jager M, et al. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007;97:315-21
  • Zhou F, Wei DZ, Tong WY, et al. Some characteristics and purification of anti-(human ovarian carcinoma)xanti-(human CD3) single-chain bispecific antibody. Biotechnol Appl Biochem 2007;47:39-47
  • Chan JK, Hamilton CA, Cheung MK, et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 2006;12:1859-67
  • Buhler P, Wolf P, Gierschner D, et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother 2008;57:43-52
  • Schlereth B, Kleindienst P, Fichtner I, et al. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Cancer Immunol Immunother 2006;55:785-96
  • Hartmann F, Renner C, Jung W, et al. Treatment of refractory Hodgkin's disease with an anti-CD16/Cd30 bispecific antibody [published erratum appears in Blood 1998, 91:1832]. Blood 1997;89:2042-7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.